Michael D Hogarty
Overview
Explore the profile of Michael D Hogarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
7217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Ambros I, Tonini G, Potschger U, Gross N, Mosseri V, Beiske K, et al.
J Clin Oncol
. 2020 Sep;
38(31):3685-3697.
PMID: 32903140
Purpose: For localized, resectable neuroblastoma without amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome. Patients...
22.
Moreno L, Barone G, Dubois S, Molenaar J, Fischer M, Schulte J, et al.
Eur J Cancer
. 2020 Jul;
136:52-68.
PMID: 32653773
Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012...
23.
McNerney K, Karageorgos S, Hogarty M, Bassiri H
Front Immunol
. 2020 May;
11:873.
PMID: 32457760
Neuroblastoma (NB) is the most common extracranial solid tumor in children and, in the high-risk group, has a 5-year mortality rate of ~50%. The high mortality rate and significant treatment-related...
24.
Hogarty M, Hunger S
Pediatr Blood Cancer
. 2020 Apr;
67 Suppl 2:e28191.
PMID: 32275099
No abstract available.
25.
Burns A, Ackerman K, Thammasitboon S, Rassbach C, Ward M, Blankenburg R, et al.
Pediatr Res
. 2020 Mar;
88(2):163-167.
PMID: 32179872
No abstract available.
26.
Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, et al.
Nat Commun
. 2020 Feb;
11(1):913.
PMID: 32060267
Aggressive cancers often have activating mutations in growth-controlling oncogenes and inactivating mutations in tumor-suppressor genes. In neuroblastoma, amplification of the MYCN oncogene and inactivation of the ATRX tumor-suppressor gene correlate...
27.
Harrington C, Sotillo E, Robert A, Hayer K, Bogusz A, Psathas J, et al.
Leukemia
. 2019 Nov;
34(5):1485.
PMID: 31758088
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
28.
Park J, Kreissman S, London W, Naranjo A, Cohn S, Hogarty M, et al.
JAMA
. 2019 Aug;
322(8):746-755.
PMID: 31454045
Importance: Induction chemotherapy followed by high-dose therapy with autologous stem cell transplant and subsequent antidisialoganglioside antibody immunotherapy is standard of care for patients with high-risk neuroblastoma, but survival rate among...
29.
Twist C, Schmidt M, Naranjo A, London W, Tenney S, Marachelian A, et al.
J Clin Oncol
. 2019 Aug;
37(34):3243-3255.
PMID: 31386611
Purpose: The primary objective of the Children's Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based...
30.
Harrington C, Sotillo E, Robert A, Hayer K, Bogusz A, Psathas J, et al.
Leukemia
. 2019 Mar;
33(10):2429-2441.
PMID: 30914792
Therapeutic targeting of initiating oncogenes is the mainstay of precision medicine. Considerable efforts have been expended toward silencing MYC, which drives many human cancers including Burkitt lymphomas (BL). Yet, the...